Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (15590)	2/21/1998 7:06:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< Bob, is that the British spelling ? :) >> Actually, yes. Bob is spelled the same way in England: Bob. However, backwards, it does not have the same British spelling. Hmmmm!? Just checking out LGND's capitalization. The "Groups" service here on SI gives some nice comparative stats. But, it would be nice to compare capitalizations based on pipelines, affiliations, revenue expectations, etc. For instance: If you compare LGND's Targretin partner Eli Lilly's capitalization of $70,146.6 million (a full blown drug company), with LGND's capitalization of $514.3 million; LLY is valued at 136 times LGND. If LGND can grow into a LLY, it would be worth almost $2000 per share. Of course, if frogs had wings, they could fly. Regards, Bob